A Phase 3 interventional study of Lurasidone 40 mg and Lurasidone 80 mg in Schizophrenia, sponsored by Sumitomo Pharma America, Inc.. Completed at 90 sites in 17 countries. Open to participants aged 13 Years to 17 Years. Per ClinicalTrials.gov, last updated 2017-04-18.
Sponsored by Sumitomo Pharma America, Inc. (part of Sumitomo Pharma Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing lurasidone in Schizophrenia — none open to participants now, none under way, none of them phase 3. lurasidone · Schizophrenia.
Among the 39 studies testing lurasidone in Schizophrenia, this one is the 12th largest by enrollment, is one of 5 that started in 2013, is one of 18 in phase 3, and was the 26th registered.
3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.
Browse Schizophrenia studies →None of the 39 studies testing lurasidone in Schizophrenia is open now. The open studies under Schizophrenia, anywhere →
lurasidone: first FDA approval 2010 (LATUDA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 13 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 5 started in 2013.
This study's enrollment of 327 is above the median of 71 across 2,947 interventional studies indexed under Schizophrenia.
Median enrollment 149 across the 39 interventional studies. Of the 38 that completed or were terminated, 27 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 39 have an industry lead sponsor. The 10 most frequent:
This study is registered under Sumitomo Pharma America, Inc., one of the names counted as Sumitomo Pharma Co., Ltd.. Under that name alone:
Sumitomo Pharma America, Inc. is the lead sponsor of 181 studies on the registry; 5 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 21 (64%) have results posted.
40 studies in Schizophrenia by Sumitomo Pharma Co., Ltd.: none open now, none under way, none of them phase 3. Of 40 finished, 28 (70%) have results posted.
Among the 40 studies in Schizophrenia by Sumitomo Pharma Co., Ltd., this one is the 13th largest by enrollment of the 39 interventional ones that give a count, is one of 4 that started in 2013, is one of 21 in phase 3, and was the 26th registered.
Sumitomo Pharma Co., Ltd.’s Schizophrenia studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 39 studies testing lurasidone in Schizophrenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sumitomo Pharma Co., Ltd.’s 40 in Schizophrenia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Efficacy and Safety study of Lurasidone in pediatric patients.
To evaluate the efficacy of lurasidone (40 mg/day and 80 mg/day) compared with placebo in adolescent subjects with schizophrenia (diagnosed by Diagnostic and Statistical Manual of Mental Disorders, 4th Ed., Text Revision [DSM-IV-TR] criteria) as measured by the change from Baseline in the Positive and Negative Syndrome Scale (PANSS) total score at Week 6.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
are unable to become pregnant (eg, premenarchal, surgically sterile, etc.); -OR-
practices true abstinence (consistent with lifestyle) and must agree to remain abstinent from signing informed consent to at least 30 days after the last dose of study drug has been taken;
-OR-
are sexually active and willing to use a medically effective method of (e.g., male using condom and female using condom, diaphragm, contraceptive sponge, spermicide, contraceptive pill, or intrauterine device) from signing informed consent to at least 7 days after the last dose of study drug has been taken.
Exclusion Criteria:
Documented history of chromosomal disorder with developmental impairment (ie, trisomy chromosome 21; 22q11 deletion syndrome).
Evidence of any chronic organic disease of the CNS such as tumors, inflammation, active seizure disorder, vascular disorder, potential CNS related disorders that might occur in childhood- eg, Duchenne Muscular dystrophy, myasthenia gravis, or other neurologic or serious neuromuscular disorders. In addition, subjects must not have a history of persistent neurological symptoms attributable to serious head injury. Past history of febrile seizure, drug-induced seizure, or alcohol withdrawal seizure is not exclusionary.
Note: Active medical conditions that are minor or well-controlled are not exclusionary if they do not affect risk to the subject or the study results. In cases in which the impact of the condition upon risk to the subject or study results is unclear, the Medical Monitor should be consulted. Any subject with a known cardiovascular disease or condition (even if controlled) must be discussed with the Medical Monitor during screening.
Note: If any laboratory results are outside the normal range, the site may have the subject retested. If upon retesting the value remains outside the normal range, the significance of this value must be discussed with the Medical Monitor for enrollment consideration.
Positive test results at screening or Baseline for:
Random (non-fasting) screening glucose is \< 200 mg/dl (11.1 mmol/L); and If ≥ 200 mg/dL (11.1 mmol/L) must be retested in a fasted state. Retested fasted value cannot be ≥ 126 mg/dL.
≤ 6.5%; and If a subject is currently being treated with oral anti-diabetic medication(s), the dose must have been stable for at least 4 weeks prior to screening. Such medication may be adjusted or discontinued during the study, as clinically indicated.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Lurasidone 40 mg once daily
Drug: Lurasidone 40 mg
Lurasidone 80 mg once daily Arm received the Lurasidone 40mg dose first, from Days 1-3, and then received the Lurasidone 80 mg dose from day 4 to Week 6
Drug: Lurasidone 80 mg
Placebo 40 or 80 mg once daily
Drug: Placebo 40 or 80 mg
Lurasidone 40 mg once daily
Also known as: Latuda
Lurasidone 80 mg once daily
Also known as: Latuda
Placebo 40 or 80 mg once daily
Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6.
PANNS total score: Changes from baseline over time - mixed model for repeated measures at week 6 -PANSS total score may range from 30 to 210- Higher values of PANSS total score represent greater severity of illness LS Mean and SE for change from baseline are based on Mixed Model for Repeated Measures with fixed effects terms for treatment, visit (as a categorical variable), pooled country, age strata, PANSS total score at baseline, and treatment-by-visit interaction.
Time frame: Baseline to 6 weeks
Change From Baseline in Clinical Global Impression Severity (CGI-S) Scale
Clinical Global Impression severity (CGI-S): Changes from baseline over time-mixed model for repeated measures- scale from 1-7 - 1=normal, not at all ill; 7=among the most extremely ill patients. LS Mean and SE for change from baseline are based on Mixed Model for Repeated Measures with fixed effects terms for treatment, visit (as a categorical variable), pooled country, age strata, CGIS at baseline, and treatment-by-visit interaction.
Time frame: baseline, week 6
Change From Baseline in PANSS Positive Subscale Scores
PANSS positive subscale score: changes from baseline over time - mixed model for repeated measures -Positive subscale (range 7-49): sum of Items P1 to P7 in the positive subscale - Higher values of PANSS Positive Subscale Score represent greater severity of illness LS Mean and SE for change from baseline are based on Mixed Model for Repeated Measures with fixed effects terms for treatment, visit (as a categorical variable), pooled country, age strata, corresponding PANSS subscale score at baseline, and treatment-by-visit interaction.
Time frame: baseline, week 6
Change From Baseline in PANSS Positive, Negative Subscale Scores
PANSS Negative subscale score: changes form baseline over time - Mixed model for repeated measures - - Negative subscale (range 7-49): sum of Items N1 to N7 in the negative subscale - Higher values of PANSS Negative Subscale Score represent greater severity of illness LS Mean and SE for change from baseline are based on Mixed Model for Repeated Measures with fixed effects terms for treatment, visit (as a categorical variable), pooled country, age strata, corresponding PANSS subscale score at baseline, and treatment-by-visit interaction.
Time frame: baseline, week 6
Proportion of Responders, Where Response is Based on ≥ 20% Improvement From Baseline in PANSS Total Score at Week 6
PANSS responder analysis over time: achieving \>= 20% reduction from baseline
Time frame: week 6
Change From Baseline in Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q)
PQ-LES-Q percentage maximum possible score: summary statistics over time - PQ-LES-Q % maximum possible score can range from 0% to 100%. Higher scores indicate better quality of life. LS Mean and SE for change from baseline are from an ANCOVA model including factors of treatment, pooled country and age group (stratification factor), and corresponding Baseline score as covariate and LOCF approach.
Time frame: baseline, week 6
Change From Baseline in Clinician-rated Children's Global Assessment Scale (CGAS)
Clinician-rated Children's Global Assessment Scale (CGAS) score: summary statistics over time - CGAS is a numeric scale (1 through 100) , where 1 represents the most impaired functioning and 100, superior functioning LS Mean and SE for change from baseline are from an ANCOVA model including factors of treatment, pooled country and age group (stratification factor), and corresponding Baseline score as covariate and LOCF approach.
Time frame: baseline, week 6
Change From Baseline in PANSS General Psychopathology Subscale Scores
PANSS general psychopathology subscale score: changes from baseline over time - mixed model for repeated measures -- General psychopathology (range 16-112): sum of Items G1 to G16 in the general psychopathology subscale -Higher values of PANSS General Psychopathology Subscale Score represent greater severity of illness LS Mean and SE for change from baseline are based on Mixed Model for Repeated Measures with fixed effects terms for treatment, visit (as a categorical variable), pooled country, age strata, corresponding PANSS subscale score at baseline, and treatment-by-visit interaction.
Time frame: baseline, week 6
Change From Baseline in PANSS Excitability Subscale Scores
Excitability subscale scores (range 4-28): consists of the following four items from the PANSS: excitement, hostility, uncooperativeness, and poor impulse control * Higher values of PANSS Excitability Subscale Score represent greater severity of illness LS Mean and SE for change from baseline are based on Mixed Model for Repeated Measures with fixed effects terms for treatment, visit (as a categorical variable), pooled country, age strata, corresponding PANSS subscale score at baseline, and treatment-by-visit interaction.
Time frame: baseline, week 6
| Milestone | Lurasidone 40 mg | Lurasidone 80 mg | Placebo |
|---|---|---|---|
| Started | 108 | 106 | 113 |
| Completed | 96 | 96 | 93 |
| Not completed | 12 | 10 | 20 |
| Withdrew: Adverse event | 5 | 3 | 9 |
| Withdrew: Lack of efficacy | 1 | 2 | 4 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 5 | 5 | 4 |
| Withdrew: Accidental randomization | 0 | 0 | 1 |
| Withdrew: Subject left study | 1 | 0 | 0 |
PANNS total score: Changes from baseline over time - mixed model for repeated measures at week 6 -PANSS total score may range from 30 to 210- Higher values of PANSS total score represent greater severity of illness LS Mean and SE for change from baseline are based on Mixed Model for Repeated Measures with fixed effects terms for treatment, visit (as a categorical variable), pooled country, age strata, PANSS total score at baseline, and treatment-by-visit interaction.
| units on a scale | Lurasidone 40 mg | Lurasidone 80 mg | Placebo |
|---|---|---|---|
| baseline | 94.5 ± 10.97 | 94.0 ± 11.12 | 92.8 ± 11.08 |
| Week 6 | -18.6 ± 1.59 | -18.3 ± 1.60 | -10.5 ± 1.59 |
Clinical Global Impression severity (CGI-S): Changes from baseline over time-mixed model for repeated measures- scale from 1-7 - 1=normal, not at all ill; 7=among the most extremely ill patients. LS Mean and SE for change from baseline are based on Mixed Model for Repeated Measures with fixed effects terms for treatment, visit (as a categorical variable), pooled country, age strata, CGIS at baseline, and treatment-by-visit interaction.
| units on a scale | Lurasidone 40 mg | Lurasidone 80 mg | Placebo |
|---|---|---|---|
| baseline | 4.9 ± 0.62 | 4.8 ± 0.66 | 4.8 ± 0.61 |
| week 6 | -0.97 ± 0.093 | -0.92 ± 0.093 | -0.50 ± 0.094 |
PANSS positive subscale score: changes from baseline over time - mixed model for repeated measures -Positive subscale (range 7-49): sum of Items P1 to P7 in the positive subscale - Higher values of PANSS Positive Subscale Score represent greater severity of illness LS Mean and SE for change from baseline are based on Mixed Model for Repeated Measures with fixed effects terms for treatment, visit (as a categorical variable), pooled country, age strata, corresponding PANSS subscale score at baseline, and treatment-by-visit interaction.
| units on a scale | Lurasidone 40 mg | Lurasidone 80 mg | Placebo |
|---|---|---|---|
| baseline | 24.1 ± 3.96 | 24.0 ± 4.08 | 23.4 ± 3.75 |
| week 6 | -6.3 ± 0.51 | -6.3 ± 0.51 | -3.1 ± 0.51 |
PANSS Negative subscale score: changes form baseline over time - Mixed model for repeated measures - - Negative subscale (range 7-49): sum of Items N1 to N7 in the negative subscale - Higher values of PANSS Negative Subscale Score represent greater severity of illness LS Mean and SE for change from baseline are based on Mixed Model for Repeated Measures with fixed effects terms for treatment, visit (as a categorical variable), pooled country, age strata, corresponding PANSS subscale score at baseline, and treatment-by-visit interaction.
| units on a scale | Lurasidone 40 mg | Lurasidone 80 mg | Placebo |
|---|---|---|---|
| baseline | 24.2 ± 4.32 | 24.5 ± 4.37 | 24.4 ± 4.01 |
| week 6 | -4.0 ± 0.48 | -3.8 ± 0.49 | -2.3 ± 0.49 |
PANSS responder analysis over time: achieving \>= 20% reduction from baseline
| number of participants | Lurasidone 40 mg | Lurasidone 80 mg | Placebo |
|---|---|---|---|
| Proportion of Responders, Where Response is Based on ≥ 20% Improvement From Baseline in PANSS Total Score at Week 6 | 69 | 47 | 69 |
PQ-LES-Q percentage maximum possible score: summary statistics over time - PQ-LES-Q % maximum possible score can range from 0% to 100%. Higher scores indicate better quality of life. LS Mean and SE for change from baseline are from an ANCOVA model including factors of treatment, pooled country and age group (stratification factor), and corresponding Baseline score as covariate and LOCF approach.
| units on a scale | Lurasidone 40 mg | Lurasidone 80 mg | Placebo |
|---|---|---|---|
| baseline | 51.3 ± 17.26 | 53.6 ± 18.50 | 52.5 ± 15.67 |
| week 6 | 5.6 ± 1.28 | 6.1 ± 1.30 | 0.3 ± 1.24 |
Clinician-rated Children's Global Assessment Scale (CGAS) score: summary statistics over time - CGAS is a numeric scale (1 through 100) , where 1 represents the most impaired functioning and 100, superior functioning LS Mean and SE for change from baseline are from an ANCOVA model including factors of treatment, pooled country and age group (stratification factor), and corresponding Baseline score as covariate and LOCF approach.
| units on a scale | Lurasidone 40 mg | Lurasidone 80 mg | Placebo |
|---|---|---|---|
| baseline | 44.2 ± 9.33 | 44.6 ± 8.11 | 43.9 ± 8.34 |
| week 6 | 11.3 ± 1.16 | 11.9 ± 1.18 | 7.5 ± 1.17 |
PANSS general psychopathology subscale score: changes from baseline over time - mixed model for repeated measures -- General psychopathology (range 16-112): sum of Items G1 to G16 in the general psychopathology subscale -Higher values of PANSS General Psychopathology Subscale Score represent greater severity of illness LS Mean and SE for change from baseline are based on Mixed Model for Repeated Measures with fixed effects terms for treatment, visit (as a categorical variable), pooled country, age strata, corresponding PANSS subscale score at baseline, and treatment-by-visit interaction.
| units on a scale | Lurasidone 40 mg | Lurasidone 80 mg | Placebo |
|---|---|---|---|
| baseline | 46.2 ± 6.65 | 45.5 ± 7.03 | 45.0 ± 6.94 |
| week 6 | -8.1 ± 0.80 | -8.1 ± 0.81 | -5.3 ± 0.80 |
Excitability subscale scores (range 4-28): consists of the following four items from the PANSS: excitement, hostility, uncooperativeness, and poor impulse control * Higher values of PANSS Excitability Subscale Score represent greater severity of illness LS Mean and SE for change from baseline are based on Mixed Model for Repeated Measures with fixed effects terms for treatment, visit (as a categorical variable), pooled country, age strata, corresponding PANSS subscale score at baseline, and treatment-by-visit interaction.
| units on a scale | Lurasidone 40 mg | Lurasidone 80 mg | Placebo |
|---|---|---|---|
| baseline | 10.8 ± 2.91 | 11.1 ± 3.07 | 10.7 ± 3.23 |
| week 6 | -0.6 ± 0.33 | -1.7 ± 0.33 | -2.4 ± 0.33 |
Collected over Treatment-emergent adverse event (TEAE) is defined as an AE with a start date on or after the date of first dose through 7 days after study drug discontinuation (14 days for serious adverse events and deaths) for subjects who complete the double blind study but do not enter into the extension study or early discontinue during the double blind study), or through the last study day of the doubleblind period for subjects continuing into the extension study.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lurasidone 40 mg | — | 4/110 (3.6%) | 70/110 (63.6%) |
| Lurasidone 80 mg | — | 2/104 (1.9%) | 67/104 (64.4%) |
| Placebo | — | 9/112 (8%) | 53/112 (47.3%) |
| Event | Lurasidone 40 mg | Lurasidone 80 mg | Placebo |
|---|---|---|---|
| schizophreniaPsychiatric disorders | 2/110 | 2/104 | 7/112 |
| Homicidal IdeationPsychiatric disorders | 1/110 | 0/104 | 0/112 |
| DiarrhoeaGastrointestinal disorders | 1/110 | 0/104 | 0/112 |
| Psychotic DisorderPsychiatric disorders | 0/110 | 0/104 | 1/112 |
| Suicidal IdeationPsychiatric disorders | 0/110 | 0/104 | 1/112 |
| Event | Lurasidone 40 mg | Lurasidone 80 mg | Placebo |
|---|---|---|---|
| NauseaGastrointestinal disorders | 14/110 | 15/104 | 3/112 |
| HeadacheNervous system disorders | 7/110 | 11/104 | 14/112 |
| SomnolenceNervous system disorders | 10/110 | 12/104 | 6/112 |
| AnxietyPsychiatric disorders | 11/110 | 3/104 | 9/112 |
| AkathisiaNervous system disorders | 10/110 | 9/104 | 2/112 |
| InsomniaPsychiatric disorders | 6/110 | 7/104 | 10/112 |
| VomitingGastrointestinal disorders | 9/110 | 7/104 | 2/112 |
| AgitationPsychiatric disorders | 5/110 | 6/104 | 5/112 |
| SedationNervous system disorders | 6/110 | 2/104 | 2/112 |
two subjects from the lurasidone 80mg (originally 106) group transferred to the lurasidone 40 mg (originally 108) group
| Age, Categorical(Participants) | Lurasidone 40 mg | Lurasidone 80 mg | Placebo | Total |
|---|---|---|---|---|
| <=18 years | 110 | 104 | 112 | 326 |
| Between 18 and 65 years | 0 | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | Lurasidone 40 mg | Lurasidone 80 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 15.5 ± 1.33 | 15.3 ± 1.35 | 15.3 ± 1.37 | 15.4 ± 1.35 |
| Age, Customized(Participants) | Lurasidone 40 mg | Lurasidone 80 mg | Placebo | Total |
|---|---|---|---|---|
| 13-15 years old | 50 | 55 | 55 | 160 |
| 16-17 years old | 60 | 49 | 57 | 166 |
| Sex: Female, Male(Participants) | Lurasidone 40 mg | Lurasidone 80 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 67 | 70 | 71 | 208 |
| Male | 43 | 34 | 41 | 118 |
| Ethnicity (NIH/OMB)(Participants) | Lurasidone 40 mg | Lurasidone 80 mg | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 13 | 18 | 13 | 44 |
| Not Hispanic or Latino | 97 | 86 | 99 | 282 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Lurasidone 40 mg | Lurasidone 80 mg | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 6 | 4 | 5 | 15 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 20 | 18 | 22 | 60 |
| White | 73 | 73 | 74 | 220 |
| More than one race | 11 | 9 | 11 | 31 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Lurasidone 40 mg | Lurasidone 80 mg | Placebo | Total |
|---|---|---|---|---|
| North America | 38 | 35 | 37 | 110 |
| South America | 9 | 8 | 9 | 26 |
| Europe | 5 | 57 | 61 | 123 |
| Southeast Asia | 2 | 1 | 1 | 4 |
| East Asia | 2 | 1 | 1 | 4 |
| Baseline BMI Percentile(participants) | Lurasidone 40 mg | Lurasidone 80 mg | Placebo | Total |
|---|---|---|---|---|
| < 3th percentile | 0 | 1 | 1 | 2 |
| > 3th to 85th percentile | 74 | 65 | 72 | 211 |
| >97th percentile | 6 | 6 | 8 | 20 |
3 further baseline measures are reported on the registry.
The record gives a start of Aug 2013, a primary completion of Dec 2015 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2017, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lurasidone
Sumitomo Pharma America, Inc. →